BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25001943)

  • 1. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
    Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of autologous plasma and gentamicin on immunophenotype and viability of cytokine-induced killer cells].
    Cao J; Yin W; Chen C; Luo X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Sep; 30(9):906-8. PubMed ID: 25200150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
    He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Killing activity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines].
    Li SJ; Zhang LS; Chai Y; Zhang YF; Zhang YM; Zeng PY; Wu CY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):733-7. PubMed ID: 18396683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The proliferation, phenotype change and anti-tumor activity of cytokine induced killer cells].
    Cao JP; Jiang ZM; Zhang XC; Lin D; Chen W; Sun YH; Ma DC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):583-6. PubMed ID: 16143062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.
    Tao Q; Chen T; Tao L; Wang H; Pan Y; Xiong S; Zhai Z
    J Immunother; 2013; 36(9):462-7. PubMed ID: 24145357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological characteristics of PHA-induced CIK cells and its killing activity to K562 cells].
    Huang MZ; Bai J; Li FS; Liu YL; Li MM; Li YH; Zhang LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):64-8. PubMed ID: 24598653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Killer Group 2A Expressed on Both Peripheral CD3
    Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
    J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.